Peroxisome Proliferator–Activated Receptor Study - PPAR Study

Description:

The goal of the trial was to evaluate treatment with the peroxisome proliferator–activated receptor (PPAR) agonist rosiglitazone compared with placebo in patients with metabolic syndrome undergoing percutaneous coronary intervention (PCI).